2026-01-26 - Analysis Report
**Comprehensive Analysis of Novo Nordisk (NVO)**

**Company Overview**
Novo Nordisk is a Danish global healthcare company that discovers, develops, manufactures, and markets pharmaceuticals and healthcare products.

**Return Rate Analysis**
- Cumulative return of review stock: **95.24%**
- Cumulative return of comparison stock (S&P 500, VOO): **126.41%**
- Divergence: **-30.90** (difference in cumulative return)
- Relative divergence: **12.90%** (located at the top 12.90% percentile of past data)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 4.0% | 18.2% | -8.0% | 102.4B |
| 2017-2019  | 54.0% | 14.1% | 28.0% | 128.6B |
| 2018-2020  | 23.0% | 23.6% | -1.0% | 155.2B |
| 2019-2021  | 118.0% | 23.6% | 53.0% | 248.8B |
| 2020-2022  | 116.0% | 23.6% | 109.0% | 300.7B |
| 2021-2023  | 208.0% | 19.9% | 187.0% | 459.7B |
| 2022-2024  | 78.0% | 41.1% | 48.0% | 382.2B |
| 2023-2025  | -98.0% | 67.0% | -173.0% | 226.1B |

**Recent Stock Price Fluctuations**
- Close: **$62.26**
- 5-day SMA: **$61.36**
- 20-day SMA: **$56.87**
- 60-day SMA: **$51.26**
- Last-market: {'price': 62.26, 'previousClose': 62.23, 'change': 0.05}

**RSI, PPO Index Indicators**
- RSI: **73.09**
- PPO: **0.53**
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: **4.50** (+) improving
- 7-day Rank change: **0** (0): flat
- 7-day Dynamic Expected Return change: **0.00** (0): flat
- Expected Return (%): **1024.30%**, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events**
- **2026-01-25**: Is Novo Nordisk (NYSE:NVO) Still Attractive After Recent 27.8% One-Year Share Price Decline? - Yahoo Finance Singapore
- **2026-01-21**: Novo: Back From The Dead (NYSE:NVO) - Seeking Alpha
- **2026-01-23**: Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock? - Investor's Business Daily
- **2026-01-21**: Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.
- **2026-01-06**: Novo Nordisk: NVO Stock To $100? - Forbes
- **2026-01-20**: ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO) - TipRanks

**Analyst Opinions**
- Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): **2.38** (~Buy)
- Opinions: **11**
- Target Price (avg/high/low): **$58.26** / **$74.99** / **$42.63**

**Comprehensive Analysis**
Novo Nordisk (NVO) has a cumulative return of **95.24%**, lower than the comparison stock (S&P 500, VOO) with a cumulative return of **126.41%**. The divergence and relative divergence are **-30.90** and **12.90%**, indicating that NVO is currently underperforming compared to the comparison stock.

The Alpha, Beta analysis shows that NVO has a range of returns from **-98.0%** to **208.0%** across different periods, with an average Beta of 0.6. The RSI and PPO index indicators indicate a medium risk level, with a recent (20 days) relative divergence change of **4.50** (+) improving.

The recent news and significant events suggest a mixed outlook for NVO, with some articles suggesting that the company's stock price may decline further while others predict a recovery. The analyst opinions indicate a consensus of Buy with a mean rating of **2.38** (~Buy) based on **11** opinions, with a target price range of **$58.26** / **$74.99** / **$42.63**.

Overall, NVO's current performance and analyst opinions indicate a mixed outlook for the company's stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.